未名医药
(002581)
| 流通市值：37.79亿 | | | 总市值：62.21亿 |
| 流通股本：4.01亿 | | | 总股本：6.60亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 314,710,263.52 | 210,782,004.46 | 83,804,783.29 | 429,790,105.06 |
| 营业收入 | 314,710,263.52 | 210,782,004.46 | 83,804,783.29 | 429,790,105.06 |
| 利息收入 | - | - | - | 0 |
| 已赚保费 | - | - | - | 0 |
| 手续费及佣金收入 | - | - | - | 0 |
| 二、营业总成本 | 348,197,159.44 | 235,965,383.68 | 106,361,412.35 | 610,716,591.63 |
| 营业成本 | 62,188,032.99 | 40,782,935.75 | 16,649,506.54 | 83,394,815.42 |
| 利息支出 | - | - | - | 0 |
| 手续费及佣金支出 | - | - | - | 0 |
| 退保金 | - | - | - | 0 |
| 赔付支出净额 | - | - | - | 0 |
| 提取保险合同准备金净额 | - | - | - | 0 |
| 保单红利支出 | - | - | - | 0 |
| 分保费用 | - | - | - | 0 |
| 税金及附加 | 4,885,829.59 | 3,271,040.29 | 1,549,826.38 | 6,889,219.4 |
| 销售费用 | 190,657,308.17 | 128,147,734.83 | 46,805,847.2 | 288,297,579.51 |
| 管理费用 | 74,211,796.58 | 52,561,938.92 | 35,425,326.41 | 165,002,999.06 |
| 研发费用 | 17,762,071.88 | 12,003,697.01 | 6,208,293.77 | 59,799,105.9 |
| 财务费用 | -1,507,879.77 | -801,963.12 | -277,387.95 | 7,332,872.34 |
| 其中:利息费用 | - | - | - | 9,059,866.72 |
| 其中:利息收入 | - | - | - | 1,779,969.98 |
| 加:公允价值变动收益 | - | - | - | 0 |
| 加:投资收益 | 58,962,233.78 | 2,969,342.02 | -6,740,217.64 | 172,681,752.05 |
| 净敞口套期收益 | - | - | - | 0 |
| 汇兑收益 | - | - | - | 0 |
| 资产处置收益 | -3,306,128.17 | -4,141,640.1 | -814,394.58 | -6,326,294.43 |
| 资产减值损失(新) | 424,227.83 | 424,227.83 | 424,227.83 | -303,447,921.08 |
| 信用减值损失(新) | 3,587,705.31 | 1,085,087.62 | 1,457,482.46 | 17,741,386.45 |
| 其他收益 | 797,382.73 | 589,435.65 | 281,691.02 | 6,926,366.78 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 26,978,525.56 | -24,256,926.2 | -27,947,839.97 | -293,351,196.8 |
| 加:营业外收入 | 1,941,022.61 | 1,730,543.89 | 1,662,922.08 | 228,112.9 |
| 减:营业外支出 | 1,175,099.47 | 792,830.93 | 562,128 | 20,126,867.5 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 27,744,448.7 | -23,319,213.24 | -26,847,045.89 | -313,249,951.4 |
| 减:所得税费用 | 3,742,614.69 | 1,495,427.18 | 208,294.92 | 8,885,160.87 |
| 六、净利润 | 24,001,834.01 | -24,814,640.42 | -27,055,340.81 | -322,135,112.27 |
| 持续经营净利润 | 24,001,834.01 | -24,814,640.42 | -27,055,340.81 | -322,135,112.27 |
| 归属于母公司股东的净利润 | 14,626,268.3 | -29,614,917.07 | -27,704,081.15 | -332,458,291.49 |
| 少数股东损益 | 9,375,565.71 | 4,800,276.65 | 648,740.34 | 10,323,179.22 |
| (一)基本每股收益 | 0.02 | -0.04 | -0.04 | -0.5 |
| (二)稀释每股收益 | 0.02 | -0.04 | -0.04 | -0.5 |
| 九、综合收益总额 | 24,001,834.01 | -24,814,640.42 | -27,055,340.81 | -322,135,112.27 |
| 归属于母公司股东的综合收益总额 | 14,626,268.3 | -29,614,917.07 | -27,704,081.15 | -332,458,291.49 |
| 归属于少数股东的综合收益总额 | 9,375,565.71 | 4,800,276.65 | 648,740.34 | 10,323,179.22 |
| 公告日期 | 2024-10-30 | 2024-08-28 | 2024-04-30 | 2024-04-30 |
| 审计意见(境内) | | | | 保留意见 |